NFKB1 and rheumatoid arthritis: When autologous DCs modified with an NF-κB inhibitory drug were exposed to citrullinated (Cit) peptides and administered to HLA risk genotype–positive RA patients in a proof-of-concept phase I clinical trial, the ASIT was safe, regulated inflammation, and modulated CD4+ effector T cells (12).